Market & Regulation
Takeda partners with Insilico for AI drug discovery
AI Newshigh confidence
Why it matters
- →The partnership highlights the increasing role of AI in pharmaceutical research.
- →It could accelerate the discovery and development of new drug candidates.
- →The deal positions Insilico as a significant player in AI-driven drug discovery.
Takeda has entered a strategic partnership with Insilico Medicine to utilize AI in early-stage drug discovery. The collaboration grants Takeda access to Insilico's Pharma.AI platform, which aids in target identification, molecular design, and clinical trial prediction. The deal could be worth up to $600 million, contingent on achieving various milestones. This partnership reflects Takeda's ongoing efforts to integrate AI into its drug discovery processes, potentially accelerating the development of new therapeutics. Insilico's shares rose following the announcement, indicating market confidence in the collaboration's potential.
Read originalThe story around this
Earlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
How we got here
More in Market & Regulation
© TechCrunch AIMarket & Regulationother
Judge allows NAACP lawsuit over xAI pollution to proceed
xAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
TechCrunch AI
© TechCrunch AI